Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase I cancer trials: limitations and implications.

R O Dillman1, J A Koziol

  • 1Patty and George Hoag Cancer Center, Hoag Memorial Hospital, Newport Beach, CA 92658.

Molecular Biotherapy
|September 1, 1992
PubMed
Summary

Phase I clinical trials aim to find the maximum tolerated dose (MTD) for new drugs. Strategies must address patient heterogeneity and ethical concerns for effective dose range determination.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of transcription factors responsible for dysregulated networks in human osteoarthritis cartilage by global gene expression analysis.

Osteoarthritis and cartilage·2018
Same author

Statistical shape modeling of proximal femoral shape deformities in Legg-Calvé-Perthes disease and slipped capital femoral epiphysis.

Osteoarthritis and cartilage·2013
Same author

New tricks with old dogs: personalised medicine and clinical trials.

British journal of cancer·2011
Same author

Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial.

Journal of biomedicine & biotechnology·2011
Same author

Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival.

Cancer immunology, immunotherapy : CII·2010
Same author

Letter to the editor "Comment on Proschan and Nason (2009), Biometrics 65, 316-322".

Biometrics·2010

Area of Science:

  • Clinical Pharmacology
  • Drug Development
  • Biostatistics

Background:

  • Phase I clinical trials are critical for establishing drug safety and determining the maximum tolerated dose (MTD).
  • Key challenges include optimizing drug delivery schedules, selecting appropriate starting doses, and managing patient heterogeneity.
  • Ethical considerations regarding risk-benefit balance and patient expectations are paramount.

Purpose of the Study:

  • To evaluate the goals and limitations of various Phase I clinical trial strategies.
  • To identify optimal approaches for establishing a safe and effective dose range for new therapeutics.
  • To address the complexities of patient heterogeneity in early-phase drug testing.

Main Methods:

  • Statistical analysis of different Phase I trial designs and patient allocation methods.
  • Review of common pitfalls in MTD selection and dose range determination.
  • Examination of ethical issues related to patient safety and informed consent.

Main Results:

  • Current Phase I strategies have limitations in meeting both patient efficacy expectations and scientific objectives.
  • Patient heterogeneity significantly impacts the reliability of MTD determination.
  • A single dose level may not adequately inform future efficacy studies.

Conclusions:

  • Phase I trial designs require careful consideration of statistical, ethical, and patient-centric factors.
  • Allowing patients to experience more than one dose level can enhance data quality.
  • Improved strategies are needed to balance safety, efficacy exploration, and ethical considerations in early drug development.

Related Experiment Videos